Literature DB >> 10328216

Rho GTPases are over-expressed in human tumors.

G Fritz1, I Just, B Kaina.   

Abstract

Small GTPases of the Rho family are involved in the regulation of a variety of cellular processes, such as the organization of the microfilamental network, cell-cell contact and malignant transformation. To address the question of whether Rho proteins are involved in carcinogenesis in man, we compared their expression in tumors from colon, breast and lung with that of the corresponding normal tissue originating from the same patient. As shown by Rho-specific 32P-ADP-ribosylation, as well as Western-blot analysis, the amount of RhoA protein was largely increased in all 3 types of tumors tested. The most dramatic differences in the expression of Rho GTPases were observed in breast tissue. All breast tumors analyzed showed high levels of RhoA, Rac and Cdc42 proteins, whereas in the corresponding normal tissue these Rho proteins were hardly or not detectable. Progression of breast tumors from WHO grade I to grade III was accompanied by a significant average increase in RhoA protein. Overall, increase in the amount of Rho GTPases, in particular RhoA, appears to be a frequent event in different types of human tumors. This supports the view that Rho GTPases are involved in human carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328216     DOI: 10.1002/(sici)1097-0215(19990531)81:5<682::aid-ijc2>3.0.co;2-b

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  228 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  The insert region of RhoA is essential for Rho kinase activation and cellular transformation.

Authors:  H Zong; K Kaibuchi; L A Quilliam
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Gene expression profiling of breast cancer cell lines in response to soy isoflavones using a pangenomic microarray approach.

Authors:  Samir Satih; Nasséra Chalabi; Nadège Rabiau; Rémy Bosviel; Luc Fontana; Yves-Jean Bignon; Dominique J Bernard-Gallon
Journal:  OMICS       Date:  2010-06

4.  Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts.

Authors:  Fukun Guo; Yi Zheng
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

5.  Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.

Authors:  Toshiyuki Kusama; Mutsuko Mukai; Masaharu Tatsuta; Yoshirou Matsumoto; Hiroyuki Nakamura; Masahiro Inoue
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Rational design and characterization of a Rac GTPase-specific small molecule inhibitor.

Authors:  Yuan Gao; J Bradley Dickerson; Fukun Guo; Jie Zheng; Yi Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

Review 7.  Microenvironmental control of the breast cancer cell cycle.

Authors:  Xun Guo; Yuehan Wu; Helen J Hathaway; Rebecca S Hartley
Journal:  Anat Rec (Hoboken)       Date:  2012-01-24       Impact factor: 2.064

8.  The Rho GTPase Cdc42 is required for primary mammary epithelial cell morphogenesis in vitro.

Authors:  Kristi Bray; Cord Brakebusch; Tracy Vargo-Gogola
Journal:  Small GTPases       Date:  2011-09-01

9.  Indole-3-carbinol inhibits MDA-MB-231 breast cancer cell motility and induces stress fibers and focal adhesion formation by activation of Rho kinase activity.

Authors:  Christine T Brew; Ida Aronchik; Karena Kosco; Jasmine McCammon; Leonard F Bjeldanes; Gary L Firestone
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

10.  Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA.

Authors:  Isabel Molina-Ortiz; Rubén A Bartolomé; Pablo Hernández-Varas; Georgina P Colo; Joaquin Teixidó
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.